Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902 | 0.87 | SMN1; SMN2 (0.43) | ALDH1A1MAPTCASP7CASP6FBP1 | |
| SCHEMBL27848584 | 0.85 | MAPT (0.35) | ALDH1A1MAPTCASP7CASP6GAA | |
| SCHEMBL1527741 | 0.85 | SMN1; SMN2 (0.41) | ALDH1A1MAPTCASP7CASP6GAA | |
| SCHEMBL27468546 | 0.84 | HCAR2 (0.40) | ALDH1A1MAPTCASP7CASP6GAA | |
| SCHEMBL11340041 | 0.77 | MAPT (0.42) | ALDH1A1MAPTCASP7CASP6GAA | |
| SCHEMBL7426695 | 0.76 | HPGD (0.46) | ALDH1A1MAPTGAASMN1; SMN2NPC1 | |
| SCHEMBL16832298 | 0.75 | MAPT (0.46) | ALDH1A1MAPTCASP7CASP6GAA | |
| SCHEMBL331274 | 0.75 | ALDH1A1 (0.36) | ALDH1A1MAPTCASP7CASP6FBP1 | |
| SCHEMBL16832074 | 0.75 | HCAR2 (0.34) | ALDH1A1MAPTCASP7CASP6HCAR2 | |
| SCHEMBL9760940 | 0.74 | HTT (0.35) | ALDH1A1MAPTCASP7CASP6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037346-A | Pyrazol bi-amide compounds containing 1,2,3-thiadiazole and synthetic method and application thereof | UNIV CHINA AGRICULTURAL | 2015-11-11 | — | — | CN | disclosed |
| CN-102267986-B | Pyrazole bisamide compounds as well as synthesis method and application thereof | UNIV CHINA AGRICULTURAL | 2014-04-16 | — | — | CN | disclosed |
| CN-102267986-A | Pyrazole bisamide compounds as well as synthesis method and application thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| CN-100383141-C | Pyrazolo [4,3-d] pyrimidine derivatives | PFIZER (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-100378100-C | Pyrazolo(4,3-d)pyrimidine derivatives | PFIZER (US) | 2008-04-02 | — | — | CN | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1255497-A | Process for preparing pyrazolo [4, 3-d ] pyrimidin-7-ones and intermediates thereof | PFIZER RES & DEV (IE) | 2000-06-07 | — | — | CN | disclosed |
| CN-1253561-A | Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | PFIZER LTD (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0995750-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | ALDH1A1 758/4885MAPT 3997/4885CASP7 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.